EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…
Pacvue Launches Pacvue Prism, Powering the Industry’s First Agentic Commerce Grid
Shangri-La Group Debuts ‘Dragonbeat’ with Resounding Success, Cross-Industry Collaborations with Local Creators in Art, Fashion, Gastronomy and Music
EE Power Asia 2026 to Spotlight Technologies Driving the Next Era of Electrification